Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma-Reference-Cited by-同舟云学术

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Published:2014-08-20 Issue:1 Volume:13 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Wong Deborah JL,Robert Lidia,Atefi Mohammad S,Lassen Amanda,Avarappatt Geetha,Cerniglia Michael,Avramis Earl,Tsoi Jennifer,Foulad David,Graeber Thomas G,Comin-Anduix Begonya,Samatar Ahmed,Lo Roger S,Ribas Antoni

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1186/1476-4598-13-194.pdf

Reference35 articles.

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib in melanoma with braf V600e mutation. N Engl J Med. 2011, 364: 2507-2516.

2. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J: Combined braf and Mek inhibition in melanoma with braf V600 mutations. N Engl J Med. 2012, 367: 1694-1703.

3. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB: Dabrafenib in braf-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012, 380: 358-365.

4. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R: Kinase-dead braf and oncogenic Ras cooperate to drive tumor progression through craf. Cell. 2010, 140: 209-221.

5. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: Raf inhibitors transactivate Raf dimers and Erk signalling in cells with wild-type braf. Nature. 2010, 464: 427-430.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. MAPK/ERK activation in macrophages promotes Leishmania internalization and pathogenesis;Microbes and Infection;2024-07

3. Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma;Cancer Letters;2024-04

4. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations;Cancer Discovery;2024-03-08

5. Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib;Biochemical Pharmacology;2024-01